Publications by authors named "Ian Gurrell"

Claim this Profile
T
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio.
Rasmus Jansson-Löfmark, Markus Fridén, Lassina Badolo, Christine Ahlström, Ian Gurrell

Drug Discov Today· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Ian Gurrell

Brain· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.
Rebecca Jarvis, Shu Fun Josephine Ng, Anna J Nathanson, Ross A Cardarelli, Krithika Abiraman, Ian K Gurrell

Cell Rep Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy.
Suzan M Hammond, Frank Abendroth, Larissa Goli, Jessica Stoodley, Matthew Burrell, Ian Gurrell

JCI Insight· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
Caroline M Kopruszinski, Peter Thornton, Joanne Arnold, Philip Newton, David Lowne, Ian Gurrell

Cephalalgia· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons.
M Catarina Silva, Ghata A Nandi, Sharon Tentarelli, Ian K Gurrell, Tanguy Jamier

Nat Commun· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Darren J Schofield, Lorraine Irving, Laura Calo, Anna Bogstedt, Gareth Rees, Ian Gurrell

Neurobiol Dis· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model.
George Thom, Mei-Mei Tian, Jon P Hatcher, Natalia Rodrigo, Matthew Burrell, Ian Gurrell

J Cereb Blood Flow Metab· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system.
George Thom, Jon Hatcher, Arron Hearn, Judy Paterson, Natalia Rodrigo, Ian Gurrell

MAbs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity.
Patrik Johansson, Karin Kaspersson, Ian K Gurrell, Elisabeth Bäck, Susanna Eketjäll

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na1.7.
Nigel A Swain, Dave Batchelor, Serge Beaudoin, Bruce M Bechle, Paul A Bradley, Ian K Gurrell

J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity.
Carl I Webster, Jon Hatcher, Matthew Burrell, George Thom, Peter Thornton, Ian Gurrell

Pain· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.
Hannah M Jones, Richard P Butt, Rob W Webster, Ian Gurrell, Pawel Dzygiel

Clin Pharmacokinet· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.
Anthony Harrison, Iain Gardner, Tanya Hay, Maurice Dickins, Kevin Beaumont, Ian Gurrell

Xenobiotica· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of PBPK modelling in drug discovery and development at Pfizer.
Hannah M Jones, Maurice Dickins, Kuresh Youdim, James R Gosset, Neil J Attkins, Ian K Gurrell

Xenobiotica· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.
Florian Wakenhut, Paul V Fish, M Jonathan Fray, Ian Gurrell, James E Mills

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis